Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer

Cancer arises from mutations accruing within cancer cells, but the tumor microenvironment (TME) is believed to be a major, often neglected, factor involved in therapy resistance and disease progression. Cancer-associated fibroblasts (CAFs) are prominent key components of TME most types solid tumors. Extensive research over past decade revealed their ability modulate metastasis, angiogenesis, mechanics, immunosuppression, drug access through synthesis remodeling extracellular matrix production growth factors. Thus, they considered impede response current clinical therapies. Therefore, targeting CAFs counteract these protumorigenic effects, overcome therapeutic options, an appealing emerging strategy. In this review, we discuss how affect prognosis provide overview novel therapies involving CAF-targeting agents lung pancreatic cancer.